**MTN-032**

**FGD Debriefing Report**

***Instructions:*** *This report is to be completed on the same day as the FGD and forwarded to RTI within one week of interview completion. This report should be uploaded to the FTP site as a Word document.*

|  |  |
| --- | --- |
| **Basic FGD Information:** | |
| FGD No.:  PTIDs:  Age Group (18-21 or 22-45):  CRS/CTU:  Venue: | FGD Date:  Facilitator #1:  Facilitator #2:  Note-taker:  Person Completing Form: |
| **Debriefing Summary:** | |
| 1. How did the FGD go today? (*Describe in detail your subjective impressions of how the participants behaved, their emotional reactions [excited, sad, laughed, bored, confused, disappointed etc.], whether there were any topics they seemed disinclined or nervous to discuss, and any other important information about the context and experience. Comment on whether the discussion was monopolized by few participants or if there was more equal contribution to the discussion from most or all participants.)*      1. Overall, how did participants from this FGD react to the individually presented drug level result discussions? *(Record which specific line of the adherence trajectory tool she identified with and why; record details about the participant’s emotional/physical reaction to the individual drug level results that expand upon their reaction recorded on the PSF.)*      1. What were the most important themes or ideas discussed? (*Briefly describe the most important ideas discussed within each of the main topic areas and any important issues that were raised)*    1. Community Description      * 1. Experience in ASPIRE and with the ring (e.g. participant and/or male partner engagement, opinion of the ring, influence on sex):      * 1. Factors Affecting Adherence *(distinguish between factors spontaneously mentioned and those discussed upon probing)*:      * 1. Impression of ASPIRE Results *(include information about what participants understand about the level of protection from the ring in ASPIRE and impressions of w)*:      * 1. Interest in HOPE:      * 1. Other important issues:      1. Were there any unexpected or unanticipated findings? *(Record anything unexpected, unanticipated, or new that was learned from this FGD.)*      1. Please provide a list of all participant pseudonyms and their associated MTN-032 PTID. | |